Clopidogrel for the Prevention of Atherothrombotic Events

To the Editor: In the April 20 issue Bhatt et al. reported the results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) study. 1 As a vascular neurologist, I want to highlight a specific piece of information that may be missed in the wealth of data provided in the article. Table 4 indicates that there was a marginal reduction in the risk of nonfatal stroke among patients receiving the dual antiplatelet therapy, as compared with patients receiving placebo plus aspirin, despite the fact that there were similar rates of nonfatal ischemic stroke in the two . . .